Dr. Rosenberg on Non-Metastatic Muscle Invasive Bladder Cancer Guidelines

May 25, 2017
Johnathan E. Rosenberg, MD

Partner | Cancer Centers | <b>MSKCC</b>

Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the new treatment guidelines for patients with non-metastatic muscle invasive bladder cancer.

Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the new treatment guidelines for patients with non-metastatic muscle invasive bladder cancer.

Traditionally, the only treatment for muscle invasive bladder cancer was radical cystectomy, explains Rosenberg. Following several large randomized trials, there has been a shown benefit to cisplatin-based neoadjuvant chemotherapy prior to cystectomy.

The new guidelines establish cisplatin-based neoadjuvant chemotherapy as a standard of care for these patients, states Rosenberg.


x